Pacira BioSciences (PCRX) Share-based Compensation (2010 - 2026)

Pacira BioSciences' Share-based Compensation history runs 17 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 6.97% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $56.5 million (up 7.45% YoY), while the FY2025 annual figure was $57.5 million, up 12.37% from the prior year.
• Share-based Compensation was $13.5 million for Q1 2026 at Pacira BioSciences, roughly flat from $13.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $15.5 million in Q2 2025 to a low of $11.0 million in Q2 2023.
• Historically, Share-based Compensation has averaged $12.8 million across 5 years, with a median of $12.7 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation increased 23.54% in 2025, then fell 6.97% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $12.7 million in 2022, then declined by 2.03% to $12.4 million in 2023, then dropped by 1.24% to $12.3 million in 2024, then rose by 10.05% to $13.5 million in 2025, then advanced by 0.3% to $13.5 million in 2026.
• The last three Share-based Compensation figures came in at $13.5 million (Q1 2026), $13.5 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.